secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2026-09-24T20:38:40+00:00
Accession:  0001193125-26-401110
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma dismisses Baker Tilly, appoints Ernst & Young as auditor
--------------------------------------------------------------------------

- Dismissed Baker Tilly on Sept 18, 2026; appointed EY for fiscal year ending June 30, 2027.
- Baker Tilly's FY2025/FY2026 audit reports were unqualified, with no disagreements.
- Prior material weakness in share-based compensation controls was remediated as of June 30, 2026.
- No consultations with EY on accounting matters; engagement subject to EY client acceptance.
- Company cites good corporate governance as reason for auditor transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526401110/0001193125-26-401110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526401110/bntc-20260918.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-401110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer